Dianthus Therapeutics Scores Early Phase 3 Win in CIDP: Claseprubart Hits GO Decision Ahead of Schedule

Dianthus shares surged after an early “GO” decision in Phase 3 CAPTIVATE trial of claseprubart for CIDP. Strong 50%+ response rate and clean safety profile reported. Top-line data expected by end of 2026.